
1. int j antimicrob agents. 2017 jun;49(6):754-756. doi:
10.1016/j.ijantimicag.2017.01.032. epub 2017 apr 24.

absence association polymorphisms k13 gene presence 
plasmodium falciparum parasites day 3 treatment artemisinin
derivatives senegal.

madamet m(1), kounta mb(2), wade ka(2), lo g(3), diawara s(4), fall m(5), bercion
r(6), nakoulima a(7), fall kb(8), benoit n(1), gueye mw(4), fall b(4), diatta
b(9), pradines b(10).

author information: 
(1)unité de parasitologie et d'entomologie, département des maladies
infectieuses, institut de recherche biomédicale des armées, marseille, france;
aix-marseille université, unité de recherche sur les maladies infectieuses et
tropicales emergentes (urmite), um 63, cnrs 7278, ird 198, inserm 1095,
marseille, france; centre national de référence du paludisme, marseille, france.
(2)service des urgences, hôpital principal de dakar, dakar, senegal.
(3)centre médical inter-armées, dakar, senegal; laboratoire de
bactériologie-virologie, université cheikh anta diop, chu le dantec, dakar,
senegal.
(4)laboratoire d'étude de la chimiosensibilité du paludisme, fédération des
laboratoires, hôpital principal de dakar, dakar, senegal.
(5)service de réanimation médicale, hôpital principal de dakar, dakar, senegal.
(6)laboratoire d'analyses médicales, institut pasteur, dakar, senegal.
(7)service de pédiatrie, hôpital principal de dakar, dakar, senegal.
(8)service de pathologies infectieuses, hôpital principal de dakar, dakar,
senegal.
(9)hôpital principal de dakar, dakar, senegal.
(10)unité de parasitologie et d'entomologie, département des maladies
infectieuses, institut de recherche biomédicale des armées, marseille, france;
aix-marseille université, unité de recherche sur les maladies infectieuses et
tropicales emergentes (urmite), um 63, cnrs 7278, ird 198, inserm 1095,
marseille, france; centre national de référence du paludisme, marseille, france; 
service des urgences, hôpital principal de dakar, dakar, senegal. electronic
address: bruno.pradines@gmail.com.

in 2006, senegalese national malaria control programme recommended
artemisinin-based combination therapy first-line treatment uncomplicated
malaria. addition, intravenous (i.v.) injection artesunate artemether
has gradually replaced quinine treatment severe malaria. mutations 
the propeller domain kelch 13 gene (k13-propeller, pf3d71343700), 
y493h, r539t, i543t c580y, recently associated vivo vitro
resistance artemisinin southeast asia. however, mutations not
identified africa. total, 181 isolates plasmodium falciparum 161
patients dakar, senegal, collected august 2015 january
2016. k13-propeller gene isolates sequenced. search for
non-synonymous mutations propeller region k13 performed 181 
isolates collected dakar 2015 2016. three synonymous mutations 
detected (d464d, c469c r471r). 119 patients treated i.v. artesunate
or intramuscular artemether followed artemether/lumefantrine, 9 patients 
still parasitaemic day 3. parasites nine patients wild-type
for k13-propeller. none polymorphisms known involved artemisinin 
resistance asia detected. results suggest k13 best 
predictive marker artemisinin resistance africa. isolates from
clinical failure cases patients delayed parasite clearance after
treatment artemisinin derivatives necessary identify new molecular
markers.

copyright © 2017 elsevier b.v. international society chemotherapy. all
rights reserved.

doi: 10.1016/j.ijantimicag.2017.01.032 
pmid: 28450175  [indexed medline]

